Glucose-6-phosphate dehydrogenase deficiency and the use of primaquine: top-down and bottom-up estimation of professional costs

Peixoto, Henry Maia; Brito, Marcelo Augusto Mota; Romero, Gustavo Adolfo Sierra; Monteiro, Wuelton Marcelo; Lacerda, Marcus Vinícius Guimarães de; Oliveira, Maria Regina Fernandes de.
Rev. saúde pública (Online) ; 51: 90, 2017. tab
Artigo em Inglês | LILACS | ID: biblio-1043313

Documentos relacionados

  1. Ethics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populations.
  2. Glucose-6-phosphate dehydrogenase deficiency and the use of primaquine: top-down and bottom-up estimation of professional costs.
  3. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
  4. G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost study.
  5. Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis.
  6. Association of G6PD status and haemolytic anaemia in patients receiving anti-malarial agents: a systematic review and meta-analysis.
  7. Rapid diagnostic test for G6PD deficiency in Plasmodium vivax-infected men: a budget impact analysis based in Brazilian Amazon.
  8. Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.
  9. Comparative pharmacokinetics and tissue distribution of primaquine enantiomers in mice.
  10. Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial.